Home/Pipeline/ILX-002

ILX-002

Sickle Cell Disease

Pre-clinicalActive

Key Facts

Indication

Sickle Cell Disease

Phase

Pre-clinical

Status

Active

Company

Illexcor Therapeutics

About Illexcor Therapeutics

Illexcor Therapeutics is a private, pre-clinical stage biotech founded in 2019, pivoting from an initial focus on antibody-drug conjugates for cancer to a specialized focus on oral therapies for sickle cell disease. The company's core strategy is to develop best-in-class, oral Hemoglobin S polymerization inhibitors, with ILX-002 as its lead asset, targeting a high-unmet need in a global genetic disorder. Operating in a competitive but rapidly evolving market, Illexcor's success hinges on demonstrating clinical proof-of-concept for its novel mechanism. The company is currently pre-revenue and its website suggests it is in a rebuilding phase, indicating potential ongoing strategic or operational developments.

View full company profile

Therapeutic Areas

Hematology Rare Disease

Other Sickle Cell Disease Drugs

Drug	Company	Phase	Status
ANXV	Annexin Pharmaceuticals	Research	Identified
Oxbryta® (voxelotor)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
CT-101	Cetya Therapeutics	Pre-clinical	Active - Lead candidate nominated
Endari (L-glutamine oral powder)	Emmaus Life Sciences	Approved	Commercial/Marketed
Undisclosed	Biossil	Phase 2/3	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Ramatroban (KAR101)	KARE Biosciences	Preclinical	Active
Digital Model for Sickle Cell Disease	Koneksa Health	Development/Validation	Active
Epeleuton	Afimmune	Phase 2	Active
CLY-124	Cellarity	Phase 1	Active
AB1	AkiraBio	Pre-clinical	Active
Oral Decitabine/Tetrahydrouridine	Novo Nordisk	Phase 2	Active